• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Gen­fit de­lays high-stakes PhI­II NASH read­out; Bris­tol-My­ers grabs first Op­di­vo OK in esophageal can­cer

6 years ago
News Briefing

Gilead los­es two more patent chal­lenges on HIV pill, set­ting up court­room fight in Delaware

6 years ago
R&D

Bank­rupt an­tibi­otics mak­er Ar­a­digm turns to old part­ner/in­vestor for fi­nal $3M fire sale

6 years ago
Deals

DB­V's peanut pre­ven­tion patch ap­proach­es key stage of ap­proval process

6 years ago
R&D

An­to­nio Gual­ber­to starts post-Ku­ra ca­reer at Ei­sai sub­sidiary H3; eF­FEC­TOR co-founder Siegfried Re­ich jumps to ...

6 years ago
Peer Review

Say good­bye to Toca­gen, strug­gling brain can­cer biotech to re­verse merge with Forte Bio­sciences

6 years ago
Deals

Speedy re­view and no ad­comm for Bio­Mar­in's pi­o­neer­ing he­mo­phil­ia gene ther­a­py

6 years ago
Cell/Gene Tx
FDA+

Gene ther­a­py pi­o­neer Kathy High has left Spark af­ter com­plet­ing $4.3B union with Roche

6 years ago
People
Cell/Gene Tx

Phar­ma­co­ge­net­ics: FDA re­leas­es ta­ble of gene-drug in­ter­ac­tions

6 years ago
Pharma
FDA+

Heron's Ground­hog Day; Vi­for forms JV with Fre­se­nius Kabi in Chi­na

6 years ago
News Briefing

Fresh off $100M round, GV-backed re­al-world da­ta start­up woos Duke re­searcher as CMO

6 years ago
People
Startups

Mer­ck los­es its chief dig­i­tal of­fi­cer, spot­light­ing tal­ent hunt for the hottest ti­tle in Big Phar­ma

6 years ago
People
R&D

Don't let Ab­b­Vie fool FTC with an easy di­vesti­ture, plead crit­ics in lat­est at­tack on $63B Al­ler­gan buy­out

6 years ago
Deals
Pharma

Auste­do, Teva's bright spot as it ex­e­cutes turn­around, fails two Touret­te's tri­als

6 years ago
Pharma

Armed with a batch of pos­i­tive bio­mark­er da­ta, a rare dis­ease play­er reaps $88M for the next big push in the clin­ic

6 years ago
R&D

FDA con­sol­i­dates non­clin­i­cal im­muno­tox­i­c­i­ty eval­u­a­tion guid­ance

6 years ago
FDA+

Eli Lil­ly vet Ker­ry Blan­chard takes the helm at one of Chi­na's top deal­mak­ers, steer­ing to­ward first ap­provals

6 years ago
People
China

TCR-fo­cused Im­mat­ics adds an­oth­er mar­quee name to its list of part­ners: GSK

6 years ago
Deals
Cell/Gene Tx

In­cyte's top­i­cal Jakafi scores again in eczema Phase III; Pri­or­i­ty re­view lines Roche's Tecen­triq up for new lung ...

6 years ago
News Briefing

DuPont makes an­oth­er for­ay in­to drug R&D, throw­ing its name in­to the mi­cro­bio­me hat

6 years ago
Deals

For two decades, a new vac­cine tech­nol­o­gy has been slow­ly ap­proach­ing prime time. Now, can it stop a pan­dem­ic?

6 years ago
R&D
In Focus

Cel­lec­tis boosts its cof­fers in re­vised off-the-shelf CAR-T deal with Servi­er

6 years ago
R&D

Bris­tol-My­ers shrugs off an­oth­er Op­di­vo com­bo flop as $1.74B deal goes pfffft

6 years ago
R&D

Biotech CEO who lied about cur­ing his own paral­y­sis sen­tenced to 7 years in jail

6 years ago
People
First page Previous page 853854855856857858859 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times